Accessibility Tools

Press Releases

GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022

ATLANTA, GA, October 26, 2022 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.

Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Wednesday, November 9, 2022, 4:30 PM EST

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13733113

Webcast: GeoVax Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through February 9, 2023. A telephonic replay of the call can be accessed by calling 877-660-6853 (domestic) or 201-612-7415 (international), using access code 13733113. The telephonic replay will be available until November 23, 2022.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website:


Media Relations Contact:                                                Investor Relations Contact:

Gina Cestari                                                                Rich Cockrell

6 Degrees                                                                    CG Capital

917-797-7904                                                              404-736-3838

This email address is being protected from spambots. You need JavaScript enabled to view it.                                     This email address is being protected from spambots. You need JavaScript enabled to view it.



Register to receive email alerts for GeoVax press releases
GeoVax © 2024 All Rights Reserved.
WebCenntrix Web Design